Since then, a study used clinical information from the TCGA database to assess m5C regulator alterations and the survival rate in patients and found that the p-value of the NSUN5 and ALYREF genes in HCC is less than 0.05, as well as the significant difference in the NSUN6 gene, which provides an important basis for exploring m5C regulators as potential therapeutic targets for HCC (Song et al., 2021). Here, ALYREF is linked to hepatocellular carcinoma.